Mantle cell lymphoma is an aggressive form of B-cell non-Hodgkin lymphoma (NHL). It is a relatively rare disease, constituting only about 6% of all NHL cases in the United States or about 3,000 cases per year.

The Mantle Cell Lymphoma Consortium (MCLC) was formed in January 2005 by the Lymphoma Research Foundation (LRF) and is composed of more than 100 laboratory and clinical scientists from North America and Europe focusing their research efforts on mantle cell lymphoma. The MCLC is a program designed to accelerate the pace of research in mantle cell lymphoma. Our goal is to identify effective and curative treatment strategies for mantle cell lymphoma by funding innovative clinical studies.

NEW! LRF's 6th MCL Consortium Scientific Workshop >>

To receive a copy of the Workshop summary, email jtestaverde@lymphoma.org

• Help patients and researchers find the most up-to-date and accurate information on MCL clinical trials in an easy to use format. 
• Post news items concerning MCL.
• Support research into the treatment and cure of MCL by providing members of the LRF Mantle Cell Lymphoma Consortium (MCLC) a tool for exchanging ideas and information.  The website will give MCLC members
  • An opportunity to post reports and publications to share with colleagues.
  • A communication tool that presents information and ideas as well as support to Consortium and MCL projects and meetings.
  • An interface linking researchers directly to the MCLC-ATCC Cell Bank.